Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2016 Jun;95(24):e3808.
doi: 10.1097/MD.0000000000003808.

No differences in metabolic outcomes between nadir GH 0.4 and 1.0 ng/mL during OGTT in surgically cured acromegalic patients (observational study)

Affiliations
Observational Study

No differences in metabolic outcomes between nadir GH 0.4 and 1.0 ng/mL during OGTT in surgically cured acromegalic patients (observational study)

Cheol Ryong Ku et al. Medicine (Baltimore). 2016 Jun.

Erratum in

  • Erratum: Medicine, Volume 95, Issue 24: Erratum.
    [No authors listed] [No authors listed] Medicine (Baltimore). 2016 Aug 7;95(31):e5074. doi: 10.1097/01.md.0000490009.39850.74. eCollection 2016 Aug. Medicine (Baltimore). 2016. PMID: 31265618 Free PMC article.

Abstract

Metabolic impairment is the common cause for mortality in acromegalic patients. In this study, long-term improvements of metabolic parameters were evaluated according to 2 different remission criteria.This was an observational cohort study before and up to 1 year after transsphenoidal adenomectomy (TSA). Participants were 187 patients with acromegaly. At 6 months after TSA, remitted patients with age- and sex-matched normalized IGF-1 were divided into 2 groups: remission 1 (R1), nadir growth hormone (GH) below 0.4 ng/mL; and remission 2 (R2), nadir GH between 0.4 and 1.0 ng/mL in oral glucose tolerance test (OGTT). Metabolic parameters during serial OGTTs were evaluated for 12 months. Remission was achieved in 157 (R1-136; R2-21) patients. Immediate postoperative metabolic parameters including body weight, body mass index, glucose, insulin, and free fatty acid in OGTT were all significantly improved in R1 and R2. HOMA-%β and HOMA-IR scores also improved in both R1 and R2. These improvements persisted for duration (12 months) of this study. However, no difference was present in metabolic parameters between R1 and R2. Although the patients with preoperative adrenal insufficiency presented significantly increased HOMA scores before TSA, there was no difference between classifications of deficient pituitary axes and changes of metabolic parameters after TSA. Remitted patients exhibited rapid restoration of metabolic parameters immediate postoperative period. Long-term improvements in metabolic parameters were not different between the 2 different nadir GH cut-offs, 0.4 and 1.0 ng/mL.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Changes free fatty acids during 75 g glucose tolerance test. During 75 g oral glucose tolerance tests, free fatty acids were measured serially before, at a week, at 6 months, and at 12 months after transsphenodial adenomectomy. At each period, there was no difference in fasting (A) and glucose-suppressed (B) free fatty acids between different cut-off GH values. White box: patients in remission with age-matched and sex-matched normal IGF-1 levels and nadir GH levels below 0.4 ng/mL (R1). Gray box: patients with age-matched and sex-matched normal IGF-1 levels and nadir GH levels ranging from 0.4 to 1.0 ng/mL (R2). Boxes indicate interquartile ranges. Horizontal bars indicate median levels.
Figure 2
Figure 2
Changes in HOMA scores in patients with acromegaly after transsphenoidal adenomectomy. HOMA-%β (A) and HOMA-IR (B) scores were measured in patients of Group 1 and Group 2 during the 75 g oral glucose tolerance test at 6 months after transsphenoidal adenomectomy. P values were calculated with the Wilcoxon signed rank test after comparing the values before and after transsphenoidal adenomectomy. White box: patients in remission with age-matched and sex-matched normal IGF-1 levels and nadir GH levels below 0.4 ng/mL (R1). Gray box: patients with age-matched and sex-matched normal IGF-1 levels and nadir GH levels ranging from 0.4 to 1.0 ng/mL (R2). Boxes indicate interquartile ranges. Horizontal bars indicate median levels.
Figure 3
Figure 3
Categorization of glucose homeostasis during the 75 g glucose tolerance test. According to the result of the 75 g oral glucose tolerance test, each patient was classified into one of the following 3 categories: diabetes mellitus (DM), impaired fasting glucose (IFG)/impaired glucose tolerance (IGT), and normal. No significant differences were observed between patients of R1 (A) and R2 (B).
Figure 4
Figure 4
Effect of each pituitary hormone on HOMA scores before and after transsphenoidal adenomectomy. HOMA-%β (A, C) and HOMA-IR (B, D) scores were measured before (A, B) and at 6 months after transsphenoidal adenomectomy (C, D) in patients in remission from acromegaly. P values were calculated with the Mann–Whitney U test. White box: intact secretory function of each hormone. Gray box: deficient secretory function of each hormone. Boxes indicate interquartile ranges. Horizontal bars indicate median levels.

References

    1. Melmed S. Medical progress: acromegaly. N Engl J Med 2006;355:2558–73. - PubMed
    1. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89:667–74. - PubMed
    1. Kasayama S, Otsuki M, Takagi M, et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 2000;52:549–55. - PubMed
    1. M⊘ller N, J⊘rgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009;30:152–77. - PubMed
    1. Ciresi A, Amato MC, Pivonello R, et al. The metabolic profile in active acromegaly is gender-specific. J Clin Endocrinol Metab 2013;98:E51–59. - PubMed

Publication types

MeSH terms